Here are five takeaways:
1. Fuse Medical signed a definitive purchase agreement for CPM, a privately owned distributor of implants and biologics.
2. Fuse Medical reports the transaction will be accretive to 2018. The company expects the 2018 consolidated revenues from sales and distribution to hit $35 million.
3. CPM will be Fuse Medical’s wholly owned subsidiary after the acquisition.
4. CPM distributes orthopedic implants for total joint reconstruction, sports medicine, internal and external fixation products for extremities as well as spinal implants and instrumentation.
5. CPM also provides biologics, including human allograft with cell based products, regenerative tissue and amniotic fluids.
More articles on biologics:
HSS’ Dr. Christopher Mendias earns $800k grant for stem cell research — 5 notes
Denver Bronco Derek Wolfe to undergo stem cell treatment after diagnosis from Dr. Robert Watkins — 3 things to know
How do muscle stem cells react to injury and aging? 6 insights
